Why the study?
Does single i.v. administration of COR-1 demonstrate safety and tolerability in human volunteers?
Does single i.v. administration of COR-1 demonstrate safety and tolerability in human volunteers?
The cyclic peptide COR-1 is safe and well-tolerated in humans, demonstrating ex vivo neutralization of anti-β1-adrenergic receptor antibodies and supporting its further development as a novel therapy for heart failure.
No takes yet. Share an insight, caveat, or question.
Supports further development in antibody-positive HF; provides first-in-human RCT data confirming safety and ex vivo efficacy.
Münch et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: